| Nov 6 |
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
|
| Nov 2 |
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
|
| Nov 1 |
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
|
| Oct 30 |
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
| Oct 30 |
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
|
| Oct 26 |
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
|
| Oct 24 |
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
|
| Oct 23 |
Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation
|
| Oct 22 |
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
|
| Oct 18 |
State Street Corp's Strategic Acquisition in the Biotechnology Sector
|
